Elekta AB (OTCMKTS:EKTAY) Short Interest Up 142.1% in July

Elekta AB (OTCMKTS:EKTAY) saw a large growth in short interest during the month of July. As of July 15th, there was short interest totaling 3,663 shares, a growth of 142.1% from the June 30th total of 1,513 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily volume of 9,213 shares, the short-interest ratio is currently 0.4 days.

Elekta Price Performance

EKTAY traded down $0.01 on Wednesday, reaching $4.96. The stock had a trading volume of 5,410 shares, compared to its average volume of 2,902. The firm has a 50-day moving average of $5.35 and a 200-day moving average of $5.87. Elekta has a fifty-two week low of $4.35 and a fifty-two week high of $6.93. The company has a current ratio of 0.87, a quick ratio of 0.68 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $1.83 billion, a price-to-earnings ratio of -30.97 and a beta of 1.01.

Elekta (OTCMKTS:EKTAY) last posted its earnings results on Thursday, May 28th. The company reported $0.06 EPS for the quarter. The business had revenue of $521.00 million for the quarter. Elekta had a negative net margin of 3.32% and a positive return on equity of 11.11%. As a group, sell-side analysts anticipate that Elekta will post 0.43 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Zacks Research cut shares of Elekta from a “hold” rating to a “strong sell” rating in a research report on Tuesday, June 2nd. Two investment analysts have rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Elekta Company Profile

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.